ALK and thyroid cancer: ALK-inhibitors are FDA-approved for solid tumors that harbor ALK fusions and a few patients with thyroid cancer have been included in the reported clinical trials and/or case reports, although no ALK-inhibitors are currently FDA-approved for DTC specifically.